Plexus Corp. (PLXS), a key player in the electronics manufacturing services (EMS) industry, has carved out a niche serving demanding sectors like healthcare, industrial tech, aerospace, and defense. For everyday investors eyeing steady growers amid supply chain volatility, Plexus stands out with its long-term revenue trajectory and improving efficiency. Over the past decade, the company has navigated global disruptions—from the 2018 trade tensions that briefly hammered profits to COVID-19 supply crunches in 2020 and chip shortages through 2022—emerging resilient thanks to diversified end-markets and strategic expansions, like its Malaysia facility ramp-up in 2021. But recent insider selling raises eyebrows, even as fundamentals point to a rebound. Let’s break it down.

Revenue Growth and Operational Efficiency

Revenue has been Plexus’s North Star, climbing from $2.56 billion in 2016 to a peak of $4.21 billion in 2023—a compound annual growth rate (CAGR) of about 5.7%. That’s no small feat in an EMS world prone to customer program shifts. However, 2024 saw a dip to $3.96 billion, down 6% year-over-year, likely tied to softer industrial demand and inventory destocking post-pandemic. The silver lining? Revenue per employee jumped 18% to $198,041 in 2024 from $168,412 the prior year, signaling sharper productivity as headcount trimmed from 25,000 in 2023 to 20,000. This metric matters because it shows management squeezing more output without bloating payroll—key for margins in a labor-intensive manufacturing game.

Analyst forecasts brighten the picture: revenue is pegged to rebound 2% to $4.03 billion in 2025, then accelerate 12% to $4.51 billion in 2026, $4.87 billion in 2027 (8% growth), and $5.12 billion in 2028 (5% up). If these hold, Plexus could ride tailwinds from healthcare device booms (think medtech wearables) and aerospace recovery post-Boeing woes. Gross margins support this, edging up from 8.9% in 2016 to a projected 10.1% in 2025—half a point better than 2024’s 9.6%. Higher margins mean pricing power or cost controls are kicking in, crucial for fending off low-cost Asian rivals.

Profitability and Cash Flow Surge

Earnings tell a story of resilience with hiccups. Net income hit $139 million in 2023 before slipping 20% to $112 million in 2024, mirroring the revenue pullback. Yet, earnings per share (EPS) rose to $6.39 projected for 2025 (up 57% from 2024’s $4.08), with further gains to $6.77 (2026), $7.73 (2027), and $9.30 (2028)—a robust 46% jump over four years. EPS is the retail investor’s best friend: it cuts through share count dilution (down steadily from 33 million to 27 million) to show true per-share profit growth.

Cash flow is where Plexus shines lately. Free cash flow per share exploded to $12.46 in 2024 from $2.24 the year before—a 456% surge—fueled by operating cash flow ballooning to $437 million (164% up). This funded $95 million in capex while building a fortress balance sheet. Historically volatile (negative in 2022 amid investments), FCF’s strength underscores ROIC climbing to 9.8% projected for 2025, above the 8.6% in 2024. ROIC measures how well Plexus turns invested capital into profits—vital for EMS firms heavy on factories and inventory. Compare to ROE at 12.4% projected (from 8.8% in 2024): shareholders are getting solid returns without excessive leverage.

Balance Sheet: Leaner and Meaner

Plexus has shed debt like a pro athlete dropping winter weight. Total debt plunged 43% to $138 million in 2025 from $247 million in 2024, flipping net debt to a cash-rich -$169 million position. Shareholder equity grew 10% to $1.45 billion in 2025 projections, boosting book value per share to $53.80 (11% up from 2024). This deleveraging—down from peaks like $462 million in 2022—frees up firepower for buybacks, dividends (modest but growing), or acquisitions. Working capital sits healthy at $880 million projected, cushioning against EMS cyclicality. In context, low net debt amid rising revenue forecasts screams financial flexibility, especially post-2022’s inventory glut that pressured peers.

Valuation: Reasonable but Stretched in Spots

Stock price action mirrors fundamentals unevenly. From 2016 lows around the mid-20s to recent closes, shares have multiplied roughly 7x, outpacing revenue growth thanks to margin expansion and buybacks. But 2024’s high of around 170 aligned with revenue softness, while 2023’s peak near 115 came amid $4.2 billion top-line strength. PE ratio spiked to 33x in 2024 (elevated versus historical teens) before settling toward 23x projected for 2025—still premium but justified by EPS acceleration. PS ratio at nearly 1x sales (up from 0.6x averages) and PB around 2.7x reflect growth pricing, not cheap like cyclicals but fair for a quality EMS name.

EV/FCF looks tasty at 10.7x trailing, down from sky-highs in lean years, signaling undervaluation on cash terms. Historically, when FCF per share topped $5 (like now), the stock rerated higher—correlation clear from 2020’s 7.2 FCF/sh coinciding with a doubling from pandemic lows.

Insider Activity: All Sells, No Buys

Here’s the red flag: zero insider buys across 2025-2026 data, but sells totaling over $15 million. The CEO unloaded 1,500 shares monthly like clockwork (e.g., March 2025 at high prices, continuing through February 2026), often leaving hefty remaining holdings (80k+ shares). CFO, COO, regional presidents, even the Chairman piled on—May 2025 saw six transactions, August seven, February 2026 eight. These are routine 10b5-1 plans (pre-scheduled to avoid insider trading optics), not panic dumps, and at prices near recent highs. Still, no buys amid a 2024 dip? It tempers enthusiasm, as insiders typically buy on conviction. Correlate to stock: sells ramped as shares pushed past 170-200, classic profit-taking after multi-year runs.

Analyst Outlook and Price Targets

Wall Street’s bullish: revenue and EPS ramps suggest 10-15% annual earnings growth through 2028, outstripping 5% top-line pace via efficiency. Healthcare (40%+ of mix) and defense programs could accelerate this, especially with U.S. reshoring trends post-CHIPS Act. Risks? Customer concentration (top 10 clients ~50% revenue) and macro slowdowns.

Price targets imply modest upside from recent levels: average about 2% higher, high end 9% above, low end 14% below. Not screaming buys, but holding steady amid projections—aligning with historical multiples on forward EPS. If FCF stays north of $150 million annually (as 2024’s $342 million hints), shares could push toward high targets.

Putting It Together: Buy, Hold, or Watch?

Plexus blends growth reliability with cash muscle, but 2024’s revenue stutter and insider exits warrant caution. Stock’s 7x decade run beat fundamentals, yet valuations aren’t frothy on forward metrics. For retail portfolios, it’s a hold for income-focused dividend chasers or a watch for dips below 14x forward PE. Future looks promising if execution matches forecasts—watch Q1 2026 earnings for program wins. At heart, Plexus rewards patient investors betting on medtech and aero seculars over short-term noise.

(Word count: 1,128)